Qianli Ma
Research Subjects
Qianli Ma has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Qiao Zhang
Department of Respiratory and Critical Care Medicine, Chongqing Songshan General Hospital, Chongqing, People’s Republic of China
10 shared publications- Changzheng Wang
Institute of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China
5 shared publications Hong Li
Department of Chronic Respiratory Disease Management and Rehabilitation Center, Chongqing Songshan General Hospital, Chongqing, People’s Republic of China
5 shared publicationsChangzheng Wang
Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Chongqing, Peoples R China
4 shared publications- Qiao Zhang
Chronic Respiratory Disease Care and Rehabilitation Center/Allergy Disease Center, The Chongqing Songshan General Hospital, 2 No. 69 Xinguang Avenue, Yubei Distinct, Chongqing, China.
4 shared publications Qinqin Wang
Department of Chronic Respiratory Disease Management and Rehabilitation Center, Chongqing Songshan General Hospital, Chongqing, People’s Republic of China
4 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-13
Improved COPD Epidemiological Awareness Following Standardized Education Independently Associated with Better Inhaled Medication Adherence: A Multicenter Prospective Pre-Post Study
Background: Chronic obstructive pulmonary disease (COPD) contributes substantially to global morbidity and mortality, while suboptimal inhaled medication adherence worsens clinical outcomes. Existing evidence confirms disease knowledge shapes self-medication behaviors, yet it remains unclear which distinct COPD knowledge domains correlate with adherence improvements following standardized patient education. Objective: To explore associations between changes in each domain of COPD-related knowledge and variations in inhaled medication adherence following routine outpatient standardized health education. Design and Participants: This was a multicenter, prospective, observational pre–post study. Consecutive stable COPD outpatients aged ≥ 40 years were recruited between June 2024 and June 2025 from two tertiary hospitals in Chongqing, China. Methods: All participants received 30-minute standardized education covering all 13 knowledge subdomains of the Bristol COPD Knowledge Questionnaire (BCKQ). BCKQ, Medication Adherence Report Scale (MARS), and COPD Assessment Test (CAT) were administered at baseline and 3-month follow-up. Spearman correlation and ANCOVA with Holm-Bonferroni correction were used; two supplementary sensitivity models were applied to verify result stability. Results: A total of 894 patients were included in the final analysis. Scores of the total BCKQ, MARS, and CAT all showed statistically significant changes after education (all P < 0.001). Among all 13 knowledge subdomains, only increased epidemiological knowledge scores were positively correlated with improved inhaled medication adherence (ρ = 0.43, P < 0.001). After adjusting for baseline adherence, total baseline knowledge and multiple demographic/clinical confounders, elevated epidemiological knowledge was independently associated with higher follow-up MARS scores (B = 0.33, SE = 0.04, P < 0.001). Consistent statistical significance for ΔEpidemiology was observed across two sensitivity analytical models. Baseline low adherence was 64.0%, and medication-related knowledge gains were not associated with adherence change. Conclusion: Improvements in COPD epidemiological knowledge were independently associated with greater inhaled medication adherence after standardized outpatient education. Prioritizing education on disease progression and long-term threats may be an effective strategy to optimize adherence in busy clinical settings.
- 1 November 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-13
Open AccessImproved COPD Epidemiological Awareness Following Standardized Education Independently Associated with Better Inhaled Medication Adherence: A Multicenter Prospective Pre-Post Study
Background: Chronic obstructive pulmonary disease (COPD) contributes substantially to global morbidity and mortality, while suboptimal inhaled medication adherence worsens clinical outcomes. Existing evidence confirms disease knowledge shapes self-medication behaviors, yet it remains unclear which distinct COPD knowledge domains correlate with adherence improvements following standardized patient education. Objective: To explore associations between changes in each domain of COPD-related knowledge and variations in inhaled medication adherence following routine outpatient standardized health education. Design and Participants: This was a multicenter, prospective, observational pre–post study. Consecutive stable COPD outpatients aged ≥ 40 years were recruited between June 2024 and June 2025 from two tertiary hospitals in Chongqing, China. Methods: All participants received 30-minute standardized education covering all 13 knowledge subdomains of the Bristol COPD Knowledge Questionnaire (BCKQ). BCKQ, Medication Adherence Report Scale (MARS), and COPD Assessment Test (CAT) were administered at baseline and 3-month follow-up. Spearman correlation and ANCOVA with Holm-Bonferroni correction were used; two supplementary sensitivity models were applied to verify result stability. Results: A total of 894 patients were included in the final analysis. Scores of the total BCKQ, MARS, and CAT all showed statistically significant changes after education (all P < 0.001). Among all 13 knowledge subdomains, only increased epidemiological knowledge scores were positively correlated with improved inhaled medication adherence (ρ = 0.43, P < 0.001). After adjusting for baseline adherence, total baseline knowledge and multiple demographic/clinical confounders, elevated epidemiological knowledge was independently associated with higher follow-up MARS scores (B = 0.33, SE = 0.04, P < 0.001). Consistent statistical significance for ΔEpidemiology was observed across two sensitivity analytical models. Baseline low adherence was 64.0%, and medication-related knowledge gains were not associated with adherence change. Conclusion: Improvements in COPD epidemiological knowledge were independently associated with greater inhaled medication adherence after standardized outpatient education. Prioritizing education on disease progression and long-term threats may be an effective strategy to optimize adherence in busy clinical settings.
- Open Access
- 6 July 2026
- Published by Taylor & Francis in COPD: Journal of Chronic Obstructive Pulmonary Disease
- Vol. 23 (1) , 2689394
Number Needed to Treat with Biologics in Type-2 Inflammation COPD: A Systematic Review and Meta-Analysis
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by persistent airflow limitation and respiratory symptoms [1]. An individual patient data meta-analysis showed ...
- 6 July 2026
- Published by Taylor & Francis in COPD: Journal of Chronic Obstructive Pulmonary Disease
- Vol. 23 (1) , 2689394
Open AccessNumber Needed to Treat with Biologics in Type-2 Inflammation COPD: A Systematic Review and Meta-Analysis
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by persistent airflow limitation and respiratory symptoms [1]. An individual patient data meta-analysis showed ...
- Open Access
- 9 March 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Clinical value of sputum galactomannan testing in the diagnosis of invasive pulmonary aspergillosis among chronic obstructive pulmonary disease patients
Diagnosing invasive pulmonary aspergillosis (IPA) in patients with chronic obstructive pulmonary disease (COPD) remains challenging due to the non-specific nature of imaging findings, the limited sensitivity of current diagnostic methods, and the difficulty of obtaining appropriate clinical specimens. To evaluate the diagnostic accuracy of sputum galactomannan (GM) testing in COPD patients with IPA. In this multicenter cross-sectional study, COPD patients with suspected IPA and patients with community-acquired pneumonia (CAP) were enrolled. GM testing was performed on sputum, serum, and bronchoalveolar lavage fluid (BALF) samples, while fungal culture was conducted on sputum samples. Diagnostic performance was assessed using the EORTC/MSGERC criteria as the reference standard. A total of 134 patients were included, comprising the COPD + IPA group (n = 43), the COPD + CAP group (n = 70), and the CAP group (n = 21). The areas under the receiver operating characteristic curve (AUCs) for GM detection in sputum, BALF, and serum were 0.833 (95% CI: 0.753-0.913), 0.884 (95% CI: 0.799-0.970), and 0.659 (95% CI: 0.552-0.766), respectively. The optimal cut-off values for sputum and BALF GM were 1.64 and 1.12, respectively. At these thresholds, sputum GM demonstrated a sensitivity of 79.1% and specificity of 75.7%, while BALF GM showed a sensitivity of 76.5% and specificity of 96.6%. Sputum GM testing demonstrates significant diagnostic value for IPA in COPD patients and provides a non-invasive alternative with reliable performance, making it a promising tool for preliminary screening and reducing the need for invasive procedures in clinical practice. ChiCTR2400089800.
- 9 March 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessClinical value of sputum galactomannan testing in the diagnosis of invasive pulmonary aspergillosis among chronic obstructive pulmonary disease patients
Diagnosing invasive pulmonary aspergillosis (IPA) in patients with chronic obstructive pulmonary disease (COPD) remains challenging due to the non-specific nature of imaging findings, the limited sensitivity of current diagnostic methods, and the difficulty of obtaining appropriate clinical specimens. To evaluate the diagnostic accuracy of sputum galactomannan (GM) testing in COPD patients with IPA. In this multicenter cross-sectional study, COPD patients with suspected IPA and patients with community-acquired pneumonia (CAP) were enrolled. GM testing was performed on sputum, serum, and bronchoalveolar lavage fluid (BALF) samples, while fungal culture was conducted on sputum samples. Diagnostic performance was assessed using the EORTC/MSGERC criteria as the reference standard. A total of 134 patients were included, comprising the COPD + IPA group (n = 43), the COPD + CAP group (n = 70), and the CAP group (n = 21). The areas under the receiver operating characteristic curve (AUCs) for GM detection in sputum, BALF, and serum were 0.833 (95% CI: 0.753-0.913), 0.884 (95% CI: 0.799-0.970), and 0.659 (95% CI: 0.552-0.766), respectively. The optimal cut-off values for sputum and BALF GM were 1.64 and 1.12, respectively. At these thresholds, sputum GM demonstrated a sensitivity of 79.1% and specificity of 75.7%, while BALF GM showed a sensitivity of 76.5% and specificity of 96.6%. Sputum GM testing demonstrates significant diagnostic value for IPA in COPD patients and provides a non-invasive alternative with reliable performance, making it a promising tool for preliminary screening and reducing the need for invasive procedures in clinical practice. ChiCTR2400089800.
- Open Access
- 29 October 2025
- Published by Wolters Kluwer Health in Annals of Thoracic Medicine
- Vol. 21 (1) , 46-52
A tool for recognizing asthma nonadherence during disease management: A prospective cohort study
BACKGROUND: The adherence of asthma patients remains an urgent issue that needs to be addressed, and there is still a lack of tools for the rapid identification of nonadherence. METHODS: A number of factors associated with increased risk of nonadherence were compared with adherence assessed using the Medication Adherence Report Scale for Asthma (MARS-A). Among them was the tool for recognizing asthma nonadherence (TRAN), which is the ratio between the patient’s perceived overall health measured using a 0–100 visual analog scale and their asthma control test score. The development set used data from a multicenter, prospective cohort study in asthma. The TRAN was then validated in a further test set of asthma patients. RESULTS: Data from 518 participants who completed 3-month follow-up formed the development set. TRAN was the best predictor of nonadherence as defined by MARS-A (odds ratio = 9.14; 95% confidence interval [CI]: 4.16, 20.10; P < 0.01) in univariate logistic regression analysis. Its area under the curve (AUC) for identifying nonadherent patients was 0.810 (95% CI: 0.753, 0.866), at a cutoff score of 1.08, its sensitivity was 82.0%, specificity was 84.4%, positive predictive value (PPV) was 55.8%, and negative predictive value (NPV) was 95.1%. In the validation group ( n = 175), the AUC was 0.75 with PPV and NPV at 56.4% and 90.8%, respectively. CONCLUSION: The TRAN is a simple method for the initial screening of asthma patients for potential nonadherence.
- 29 October 2025
- Published by Wolters Kluwer Health in Annals of Thoracic Medicine
- Vol. 21 (1) , 46-52
Open AccessA tool for recognizing asthma nonadherence during disease management: A prospective cohort study
BACKGROUND: The adherence of asthma patients remains an urgent issue that needs to be addressed, and there is still a lack of tools for the rapid identification of nonadherence. METHODS: A number of factors associated with increased risk of nonadherence were compared with adherence assessed using the Medication Adherence Report Scale for Asthma (MARS-A). Among them was the tool for recognizing asthma nonadherence (TRAN), which is the ratio between the patient’s perceived overall health measured using a 0–100 visual analog scale and their asthma control test score. The development set used data from a multicenter, prospective cohort study in asthma. The TRAN was then validated in a further test set of asthma patients. RESULTS: Data from 518 participants who completed 3-month follow-up formed the development set. TRAN was the best predictor of nonadherence as defined by MARS-A (odds ratio = 9.14; 95% confidence interval [CI]: 4.16, 20.10; P < 0.01) in univariate logistic regression analysis. Its area under the curve (AUC) for identifying nonadherent patients was 0.810 (95% CI: 0.753, 0.866), at a cutoff score of 1.08, its sensitivity was 82.0%, specificity was 84.4%, positive predictive value (PPV) was 55.8%, and negative predictive value (NPV) was 95.1%. In the validation group ( n = 175), the AUC was 0.75 with PPV and NPV at 56.4% and 90.8%, respectively. CONCLUSION: The TRAN is a simple method for the initial screening of asthma patients for potential nonadherence.
- Open Access
- 24 September 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1666703
Dynamic performance and scenario-based screening strategy of six COPD questionnaires: a cross-sectional study with prevalence-driven robustness validation
Introduction: Chronic Obstructive Pulmonary Disease (COPD) imposes a high global burden. Spirometry is the diagnostic gold standard but has accessibility barriers. Screening questionnaires provide a feasible alternative.Objectives: To compare the diagnostic performance and robustness of six COPD screening questionnaires (LFQ: Lung Function Questionnaire; IPAG: International Primary Care Airways Group Questionnaire; Modified-IPAG; COPD-PS: COPD Population Screener Questionnaire; COPD-SQ: COPD Screening Questionnaire; SCSQ: The Salzburg COPD Screening Questionnaire) within a single cohort population, thereby providing evidence to support targeted screening for COPD.Methods: This cross-sectional study enrolled adults ≥40 years without prior asthma or non-COPD chronic lung diseases. Participants completed six screening questionnaires and spirometry. COPD was confirmed by pulmonologists. Receiver operating characteristic (ROC) curves were constructed for each questionnaire; sensitivity, specificity, accuracy (ACC), positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) were calculated. Dynamic variations in screening performance were simulated under different disease prevalence scenarios.Results: Modified-IPAG and LFQ showed highest sensitivity (94.78%/91.79%) and NPV (98.11%/97.45%); COPD-PS and COPD-SQ had highest specificity (79.32%/87.05%) and PPV (43.50%/43.87%). AUC ranged 0.681 (SCSQ)–0.796 (COPD-PS). Dynamic simulations revealed COPD-PS maintained stable ACC across prevalence (ΔACC = 0.06; β = −0.018; P = 0.114), while SQ declined with increasing prevalence (ΔACC = 0.26; β = −0.263; P < 0.001).Conclusion: A “Scenario-Priority” strategy is proposed: For rule-out screening, use high-sensitivity tools (Modified-IPAG/LFQ); for high-risk identification, prioritize robust COPD-PS; in low-prevalence regions (<30%), use high-specificity SQ. This approach transcends the conventional “tool-first” static framework, delivering evidence-based support for precision COPD screening implementation.
- 24 September 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1666703
Open AccessDynamic performance and scenario-based screening strategy of six COPD questionnaires: a cross-sectional study with prevalence-driven robustness validation
Introduction: Chronic Obstructive Pulmonary Disease (COPD) imposes a high global burden. Spirometry is the diagnostic gold standard but has accessibility barriers. Screening questionnaires provide a feasible alternative.Objectives: To compare the diagnostic performance and robustness of six COPD screening questionnaires (LFQ: Lung Function Questionnaire; IPAG: International Primary Care Airways Group Questionnaire; Modified-IPAG; COPD-PS: COPD Population Screener Questionnaire; COPD-SQ: COPD Screening Questionnaire; SCSQ: The Salzburg COPD Screening Questionnaire) within a single cohort population, thereby providing evidence to support targeted screening for COPD.Methods: This cross-sectional study enrolled adults ≥40 years without prior asthma or non-COPD chronic lung diseases. Participants completed six screening questionnaires and spirometry. COPD was confirmed by pulmonologists. Receiver operating characteristic (ROC) curves were constructed for each questionnaire; sensitivity, specificity, accuracy (ACC), positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) were calculated. Dynamic variations in screening performance were simulated under different disease prevalence scenarios.Results: Modified-IPAG and LFQ showed highest sensitivity (94.78%/91.79%) and NPV (98.11%/97.45%); COPD-PS and COPD-SQ had highest specificity (79.32%/87.05%) and PPV (43.50%/43.87%). AUC ranged 0.681 (SCSQ)–0.796 (COPD-PS). Dynamic simulations revealed COPD-PS maintained stable ACC across prevalence (ΔACC = 0.06; β = −0.018; P = 0.114), while SQ declined with increasing prevalence (ΔACC = 0.26; β = −0.263; P < 0.001).Conclusion: A “Scenario-Priority” strategy is proposed: For rule-out screening, use high-sensitivity tools (Modified-IPAG/LFQ); for high-risk identification, prioritize robust COPD-PS; in low-prevalence regions (<30%), use high-specificity SQ. This approach transcends the conventional “tool-first” static framework, delivering evidence-based support for precision COPD screening implementation.
- Open Access
- 28 August 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (1)
Predictors of COPD exacerbations differ between grades of airflow limitation
Background: History of exacerbations is a predictor of future exacerbations in COPD but there are also predictors that are independent of exacerbation history. However, it is unclear whether their relative contribution is consistent across different degrees of airflow limitation. Methods: This analysis used data from COMPASS, a prospective study in COPD. Baseline demographics, clinical history, spirometry and patient-reported outcomes were collected. Multivariable models were created to predict moderate or severe exacerbations in the 18 months after baseline. Covariates included forced expiratory volume in 1 s (FEV 1 ) % predicted, Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade, modified Medical Research Council (mMRC) and COPD Assessment Test (CAT) scores, and exacerbation history. Goodness of fit was tested using C-statistics. Results: At baseline there were 1696 patients; 89.6% males, 46.9% current smokers, mean± sd age of 65.4±7.5 years, post-bronchodilator FEV 1 66.6±20.1% predicted and 0.5±1.0 moderate/severe exacerbations in the prior year. Over 18 months, 17.8% of patients had ≥1 moderate/severe exacerbation. The best fit model identified six independent variables, C-statistic 0.739. Subgroup analysis into GOLD grades I, II and III+IV combined showed different predictor patterns. In grade I, history of moderate exacerbations was the strongest predictor, together with chronic bronchitis and gastro-oesophageal reflux. In grades III+IV, only history of severe exacerbations and mMRC score were significant. Grade II showed an intermediate picture in which severe exacerbations, chronic bronchitis and gastro-oesophageal reflux were all significant. Conclusions: There are multiple predictors of COPD exacerbations, which differ between GOLD grades. Future predictive models for exacerbation risk should take this into account.
- 28 August 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (1)
Open AccessPredictors of COPD exacerbations differ between grades of airflow limitation
Background: History of exacerbations is a predictor of future exacerbations in COPD but there are also predictors that are independent of exacerbation history. However, it is unclear whether their relative contribution is consistent across different degrees of airflow limitation. Methods: This analysis used data from COMPASS, a prospective study in COPD. Baseline demographics, clinical history, spirometry and patient-reported outcomes were collected. Multivariable models were created to predict moderate or severe exacerbations in the 18 months after baseline. Covariates included forced expiratory volume in 1 s (FEV 1 ) % predicted, Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade, modified Medical Research Council (mMRC) and COPD Assessment Test (CAT) scores, and exacerbation history. Goodness of fit was tested using C-statistics. Results: At baseline there were 1696 patients; 89.6% males, 46.9% current smokers, mean± sd age of 65.4±7.5 years, post-bronchodilator FEV 1 66.6±20.1% predicted and 0.5±1.0 moderate/severe exacerbations in the prior year. Over 18 months, 17.8% of patients had ≥1 moderate/severe exacerbation. The best fit model identified six independent variables, C-statistic 0.739. Subgroup analysis into GOLD grades I, II and III+IV combined showed different predictor patterns. In grade I, history of moderate exacerbations was the strongest predictor, together with chronic bronchitis and gastro-oesophageal reflux. In grades III+IV, only history of severe exacerbations and mMRC score were significant. Grade II showed an intermediate picture in which severe exacerbations, chronic bronchitis and gastro-oesophageal reflux were all significant. Conclusions: There are multiple predictors of COPD exacerbations, which differ between GOLD grades. Future predictive models for exacerbation risk should take this into account.
- Open Access
- 1 August 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e56594
Quality of Chronic Obstructive Pulmonary Disease Information on the Chinese Internet: Website Evaluation Study
Background: The development of internet technology has greatly increased the ability of patients with chronic obstructive pulmonary disease (COPD) to obtain health information, giving patients more initiative in the patient-physician decision-making process. However, concerns about the quality of website health information will affect the enthusiasm of patients’ website search behavior. Therefore, it is necessary to evaluate the current situation of Chinese internet information on COPD. Objective: This study aims to evaluate the quality of COPD treatment information on the Chinese internet. Methods: Using the standard disease name “慢性阻塞性肺疾病” (“chronic obstructive pulmonary disease” in Chinese) and the commonly used public search terms “慢阻肺” (“COPD”) and “肺气肿” (“emphysema”) combined with the keyword “治疗” (“treatment”), we searched the PC client web page of Baidu, Sogou, and 360 search engines and screened the first 50 links of the website from July to August 2021. The language was restricted to Chinese for all the websites. The DISCERN tool was used to evaluate the websites. Results: A total of 96 websites were included and analyzed. The mean overall DISCERN score for all websites was 30.4 (SD 10.3; range 17.3-58.7; low quality), no website reached the maximum DISCERN score of 75, and the mean score for each item was 2.0 (SD 0.7; range 1.2-3.9). There were significant differences in mean DISCERN scores between terms, with “chronic obstructive pulmonary disease” having the highest mean score. Conclusions: The quality of COPD information on the Chinese internet is poor, which is mainly reflected in the low reliability and relevance of COPD treatment information, which can easily lead consumers to make inappropriate treatment choices. The term “chronic obstructive pulmonary disease” has the highest DISCERN score among commonly used disease search terms. It is recommended that consumers use standard disease names when searching for website information, as the information obtained is relatively reliable.
- 1 August 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e56594
Open AccessQuality of Chronic Obstructive Pulmonary Disease Information on the Chinese Internet: Website Evaluation Study
Background: The development of internet technology has greatly increased the ability of patients with chronic obstructive pulmonary disease (COPD) to obtain health information, giving patients more initiative in the patient-physician decision-making process. However, concerns about the quality of website health information will affect the enthusiasm of patients’ website search behavior. Therefore, it is necessary to evaluate the current situation of Chinese internet information on COPD. Objective: This study aims to evaluate the quality of COPD treatment information on the Chinese internet. Methods: Using the standard disease name “慢性阻塞性肺疾病” (“chronic obstructive pulmonary disease” in Chinese) and the commonly used public search terms “慢阻肺” (“COPD”) and “肺气肿” (“emphysema”) combined with the keyword “治疗” (“treatment”), we searched the PC client web page of Baidu, Sogou, and 360 search engines and screened the first 50 links of the website from July to August 2021. The language was restricted to Chinese for all the websites. The DISCERN tool was used to evaluate the websites. Results: A total of 96 websites were included and analyzed. The mean overall DISCERN score for all websites was 30.4 (SD 10.3; range 17.3-58.7; low quality), no website reached the maximum DISCERN score of 75, and the mean score for each item was 2.0 (SD 0.7; range 1.2-3.9). There were significant differences in mean DISCERN scores between terms, with “chronic obstructive pulmonary disease” having the highest mean score. Conclusions: The quality of COPD information on the Chinese internet is poor, which is mainly reflected in the low reliability and relevance of COPD treatment information, which can easily lead consumers to make inappropriate treatment choices. The term “chronic obstructive pulmonary disease” has the highest DISCERN score among commonly used disease search terms. It is recommended that consumers use standard disease names when searching for website information, as the information obtained is relatively reliable.
- Open Access
- 21 January 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Quality of Chronic Obstructive Pulmonary Disease Information on the Chinese Internet: Website Evaluation Study (Preprint)
BACKGROUND The development of internet technology has greatly increased the ability of patients with chronic obstructive pulmonary disease (COPD) to obtain health information, giving patients more initiative in the patient-physician decision-making process. However, concerns about the quality of website health information will affect the enthusiasm of patients’ website search behavior. Therefore, it is necessary to evaluate the current situation of Chinese internet information on COPD. OBJECTIVE This study aims to evaluate the quality of COPD treatment information on the Chinese internet. METHODS Using the standard disease name “慢性阻塞性肺疾病” (“chronic obstructive pulmonary disease” in Chinese) and the commonly used public search terms “慢阻肺” (“COPD”) and “肺气肿” (“emphysema”) combined with the keyword “治疗” (“treatment”), we searched the PC client web page of Baidu, Sogou, and 360 search engines and screened the first 50 links of the website from July to August 2021. The language was restricted to Chinese for all the websites. The DISCERN tool was used to evaluate the websites. RESULTS A total of 96 websites were included and analyzed. The mean overall DISCERN score for all websites was 30.4 (SD 10.3; range 17.3-58.7; low quality), no website reached the maximum DISCERN score of 75, and the mean score for each item was 2.0 (SD 0.7; range 1.2-3.9). There were significant differences in mean DISCERN scores between terms, with “chronic obstructive pulmonary disease” having the highest mean score. CONCLUSIONS The quality of COPD information on the Chinese internet is poor, which is mainly reflected in the low reliability and relevance of COPD treatment information, which can easily lead consumers to make inappropriate treatment choices. The term “chronic obstructive pulmonary disease” has the highest DISCERN score among commonly used disease search terms. It is recommended that consumers use standard disease names when searching for website information, as the information obtained is relatively reliable.
- 21 January 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessQuality of Chronic Obstructive Pulmonary Disease Information on the Chinese Internet: Website Evaluation Study (Preprint)
BACKGROUND The development of internet technology has greatly increased the ability of patients with chronic obstructive pulmonary disease (COPD) to obtain health information, giving patients more initiative in the patient-physician decision-making process. However, concerns about the quality of website health information will affect the enthusiasm of patients’ website search behavior. Therefore, it is necessary to evaluate the current situation of Chinese internet information on COPD. OBJECTIVE This study aims to evaluate the quality of COPD treatment information on the Chinese internet. METHODS Using the standard disease name “慢性阻塞性肺疾病” (“chronic obstructive pulmonary disease” in Chinese) and the commonly used public search terms “慢阻肺” (“COPD”) and “肺气肿” (“emphysema”) combined with the keyword “治疗” (“treatment”), we searched the PC client web page of Baidu, Sogou, and 360 search engines and screened the first 50 links of the website from July to August 2021. The language was restricted to Chinese for all the websites. The DISCERN tool was used to evaluate the websites. RESULTS A total of 96 websites were included and analyzed. The mean overall DISCERN score for all websites was 30.4 (SD 10.3; range 17.3-58.7; low quality), no website reached the maximum DISCERN score of 75, and the mean score for each item was 2.0 (SD 0.7; range 1.2-3.9). There were significant differences in mean DISCERN scores between terms, with “chronic obstructive pulmonary disease” having the highest mean score. CONCLUSIONS The quality of COPD information on the Chinese internet is poor, which is mainly reflected in the low reliability and relevance of COPD treatment information, which can easily lead consumers to make inappropriate treatment choices. The term “chronic obstructive pulmonary disease” has the highest DISCERN score among commonly used disease search terms. It is recommended that consumers use standard disease names when searching for website information, as the information obtained is relatively reliable.
- Open Access
- 11 March 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-10
Different Airway Inflammatory Phenotypes Correlate with Specific Fungal and Bacterial Microbiota in Asthma and Chronic Obstructive Pulmonary Disease
Background. Studies of chronic airway inflammatory diseases have increasingly focused on airway microbiota. However, the microbiota characteristics of asthma and chronic obstructive pulmonary disease (COPD) patients with different airway inflammatory phenotypes remain unclear. Objective. We aimed to reveal the differences of fungal and bacterial microbiota between eosinophilic asthma (EA) and noneosinophilic asthma (NEA) patients and between eosinophilic COPD (EC) and noneosinophilic COPD (NEC) patients. Further, explore whether similarities exist in the airway microbiota of patients with the same phenotype. Methods. Induced sputum samples were collected from 45 asthma subjects and 39 COPD subjects. The airway microbiota of the subjects was profiled by nearly full-length 16S rRNA and internal transcribed space (ITS) sequencing. Results. Subjects with eosinophilic phenotype (EA and EC) showed significant differences in both fungal and bacterial microbiota compared to the corresponding subjects with noneosinophilic phenotype (NEA and NEC). In addition, no differences were observed between the fungal microbiota of subjects with the same phenotype (EA vs. EC, NEA vs. NEC). In bacterial microbiota, the greater relative abundance of Streptococcus thermophilus was observed in EA and EC subjects, while Ochrobactrum was enriched in NEA and NEC subjects. In fungal microbiota, the EA and EC subjects showed higher relative abundances of Aspergillus and Bjerkandera, while the NEA and NEC subjects were enriched in Rhodotorula and Papiliotrema. Conclusions. Different airway inflammatory phenotypes were related to specific fungal and bacterial microbiota in both asthma and COPD, while the same airway inflammatory phenotype revealed a degree of similarity in airway microbiota, particularly in fungal microbiota.
- 11 March 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-10
Open AccessDifferent Airway Inflammatory Phenotypes Correlate with Specific Fungal and Bacterial Microbiota in Asthma and Chronic Obstructive Pulmonary Disease
Background. Studies of chronic airway inflammatory diseases have increasingly focused on airway microbiota. However, the microbiota characteristics of asthma and chronic obstructive pulmonary disease (COPD) patients with different airway inflammatory phenotypes remain unclear. Objective. We aimed to reveal the differences of fungal and bacterial microbiota between eosinophilic asthma (EA) and noneosinophilic asthma (NEA) patients and between eosinophilic COPD (EC) and noneosinophilic COPD (NEC) patients. Further, explore whether similarities exist in the airway microbiota of patients with the same phenotype. Methods. Induced sputum samples were collected from 45 asthma subjects and 39 COPD subjects. The airway microbiota of the subjects was profiled by nearly full-length 16S rRNA and internal transcribed space (ITS) sequencing. Results. Subjects with eosinophilic phenotype (EA and EC) showed significant differences in both fungal and bacterial microbiota compared to the corresponding subjects with noneosinophilic phenotype (NEA and NEC). In addition, no differences were observed between the fungal microbiota of subjects with the same phenotype (EA vs. EC, NEA vs. NEC). In bacterial microbiota, the greater relative abundance of Streptococcus thermophilus was observed in EA and EC subjects, while Ochrobactrum was enriched in NEA and NEC subjects. In fungal microbiota, the EA and EC subjects showed higher relative abundances of Aspergillus and Bjerkandera, while the NEA and NEC subjects were enriched in Rhodotorula and Papiliotrema. Conclusions. Different airway inflammatory phenotypes were related to specific fungal and bacterial microbiota in both asthma and COPD, while the same airway inflammatory phenotype revealed a degree of similarity in airway microbiota, particularly in fungal microbiota.
- Open Access
- 1 January 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 213-222
The Development of a COPD Exacerbation Recognition Tool (CERT) to Help Patients Recognize When to Seek Medical Advice
Introduction: Many patients with chronic obstructive pulmonary disease (COPD) do not report exacerbations and may benefit from simple guidance about when to seek medical attention, so we developed a COPD Exacerbation Recognition Tool (CERT). Methods: The study was run across three sites in China in patients who had an exacerbation within the previous year. Step 1: focus group qualitative study (total 48 patients) captured symptoms associated with an exacerbation. Step 2: cognitive debriefing to ensure items were appropriately worded. Step 3: 150 patients (69 years, 21% female, FEV1 63% predicted, CAT 15, 2 exacerbations in previous year) completed a questionnaire composed of the items from Steps 1 and 2 using two response options – severity during an exacerbation and magnitude of change from usual state. Responses were analysed in terms of frequency and tested for influence of demographic factors. Exploratory factor analysis (EFA) identified key domains. Using these results, an expert panel guided choice of items that formed the CERT. Results: Following Steps 1 and 2, 29 candidate items were selected for Step 3. Response rates with the two response options were very similar. There was minimal influence of demographic factors on response to the items. EFA using the 11 items with the highest response rates identified two principal factors, Factor 1: breathlessness and activity limitation (79.1% of variance), Factor 2: cough and sputum (20.9% of variance). Five items were selected for the CERT based on response rate and EFA factor loading: worsening cough, increased sputum volume, shortness of breath, laborious breathing, and limitation of motion. Sensitivity analysis suggested that worsening of two or more symptoms had good sensitivity and specificity for the presence of an exacerbation. Discussion: The CERT is an evidence-based tool to provide patients with simple-to-follow guidance about when to seek medical attention when their COPD symptoms worsen.
- 1 January 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 213-222
Open AccessThe Development of a COPD Exacerbation Recognition Tool (CERT) to Help Patients Recognize When to Seek Medical Advice
Introduction: Many patients with chronic obstructive pulmonary disease (COPD) do not report exacerbations and may benefit from simple guidance about when to seek medical attention, so we developed a COPD Exacerbation Recognition Tool (CERT). Methods: The study was run across three sites in China in patients who had an exacerbation within the previous year. Step 1: focus group qualitative study (total 48 patients) captured symptoms associated with an exacerbation. Step 2: cognitive debriefing to ensure items were appropriately worded. Step 3: 150 patients (69 years, 21% female, FEV1 63% predicted, CAT 15, 2 exacerbations in previous year) completed a questionnaire composed of the items from Steps 1 and 2 using two response options – severity during an exacerbation and magnitude of change from usual state. Responses were analysed in terms of frequency and tested for influence of demographic factors. Exploratory factor analysis (EFA) identified key domains. Using these results, an expert panel guided choice of items that formed the CERT. Results: Following Steps 1 and 2, 29 candidate items were selected for Step 3. Response rates with the two response options were very similar. There was minimal influence of demographic factors on response to the items. EFA using the 11 items with the highest response rates identified two principal factors, Factor 1: breathlessness and activity limitation (79.1% of variance), Factor 2: cough and sputum (20.9% of variance). Five items were selected for the CERT based on response rate and EFA factor loading: worsening cough, increased sputum volume, shortness of breath, laborious breathing, and limitation of motion. Sensitivity analysis suggested that worsening of two or more symptoms had good sensitivity and specificity for the presence of an exacerbation. Discussion: The CERT is an evidence-based tool to provide patients with simple-to-follow guidance about when to seek medical attention when their COPD symptoms worsen.